

# **Inhibition of the inflammatory effect of LL-37**

# **Decrease of** skin erythema

# Improvement of skin redness disorders



# **Description**

Tetrapeptide that decreases the appearance of facial redness and telangiectasia caused by an exaggerated inflammatory response. telangyn™ peptide reduces the release of interleukins (IL-6 and IL-8) induced by 37-amino-acid peptide (LL-37), cathelicidin overexpressed in skin disorders with erythema.



## **Appearance**

Translucent solution containing 0.05% Acetyl Tetrapeptide-40.

## **INCI**

Water (Aqua), Acetyl Tetrapeptide-40, Caprylyl Glycol.

## **Properties**

telangyn™ peptide fights the undesired effects caused by inflammation such as skin redness and dilated blood vessels, tissue degradation as well as post-inflammatory hyperpigmentation and dull skin.

## **Applications**

telangyn™ peptide can be incorporated into formulations designed to reduce facial redness and telangiectasia, improving even skin tone, while providing additional firming and photoprotective effects.

### **Science**

In the natural response of the immune system to potential harmful agents and conditions, kallikreins and antimicrobial compounds like cathelicidins have an important role. They induce the release of interleukines (ILs), which are among the increased molecules in facial skin redness and vascular alterations. In skin disorders with erythema and dilated blood vessels, like rosacea, LL-37 expression is found to be abnormally high, it is locally activated and a cascade of inflammatory reactions leads to an increase of pro-inflammatory metabolites, IL-6 and IL-8 among others.

The dermal connective tissue may be damaged as the proteolytic degradation of the extracellular matrix (ECM), mainly of collagen, is increased due to matrix metalloproteinases (MMPs) activation. Therefore, red areas become more visible as capillaries are fragile and permeable, and blood vessels can easily dilate due to inflammation.

telangyn™ peptide helps to decrease facial redness and other skin disorders caused by LL-37 activation and subsequent release of ILs. It also provides a photoprotective effect lowering cell damage and skin inflammation negative effects.

Dosage 2%

## **Solubility**

Water soluble.







# In vitro efficacy



### 1. INHIBITION OF LL-37-INDUCED IL RELEASE

The inhibition of the activity of LL-37 was measured by the release of the key pro-inflammatory cytokines IL-6 and IL-8 in human primary keratinocytes treated with LL-37 alone or with telangyn™ peptide. Quantification was performed by ELISA.



## telangyn™ *peptide* lowers LL-37-mediated IL-6 and IL-8 release

IL-6 levels decreased by 24.2% and IL-8, by 22.8% with **telangyn**<sup>TM</sup> peptide at 0.5 mg/mL.



# Connective tissue degradation is reduced by telangyn™ peptide

telangyn™ peptide demonstrated a statistically significant inhibitory effect on collagenase activity.

### 2. ANTI-COLLAGENASE ASSAY

The anti-collagenase effect of **telangyn**™ *peptide* was evaluated by measuring the fluorescence of the fluorescein conjugate (gelatine). Fluorescence intensity is proportional to proteolytic activity.


# In vivo efficacy

### SKIN REDNESS IMPROVEMENT

A group of 20 volunteers (aged between 25 and 65) with healthy skin but mild rosacea applied a cream containing 2% telangyn™ peptide solution twice a day for 28 days.

# • Dermatological evaluation

A trained specialist evaluated erythema, skin redness and extent intensity as well as skin roughness using a scale from no intensity to maximum intensity, after 1 and 4 weeks.






# Erythema, redness and extent intensity are reduced with telangyn™ peptide

Skin roughness diminished as well, by 7.5% at the end of the treatment.

### • Instrumental evaluation

Images of 5 volunteers were taken with a facial scanner and evaluated by an analysis software at the end of the treatment (4 weeks). Feature counts are the number of red areas and absolute scores are the size and intensity of the red areas.



telangyn<sup>™</sup> *peptide*decreases facial redness,
reducing the number
of red areas as well as
their size and intensity

The trademarks referenced in this brochure are owned by The Lubrizol Corporation or its affiliates. While the information contained herein is believed to be reliable, there are no representations, guarantees, or warranties of any kind made as to its accuracy, suitability for particular applications, how the product(s) will perform in combination with other substance or in the User's process or the results obtained. All expressed and implied warranties are disclaimed. Lubrizol and its affiliates MAKE NO WARRANTIES (FREES OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. The User is solely responsible for ensuring that products marketed to consumers comply with all relevant laws and regulations and assumes all risk and liability of any use or handling of any materials. User agrees to indemnify and hold harmless Lubrizol and its affiliates for any and all actions arising from User's use of any information including claims in this publication, including, but not limited to, use in a devertising and and finished product label claims, and not present this publication as evidence of finished product claims substantiation to any regulatory authority. It is the User's sole responsibility to determine if there are any issues relating to patent infringement relating to the supplied information. Nothing contained herein is to be considered as permission, recommendation, nor as an inducement to practice any patented invention without permission of the patent owner.